XENE vs YDES: fair value comparison
Xenon Pharmaceuticals Inc. and YD Bio Ltd · Updated 2026-10-19
XENE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. YDES has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, XENE currently ranks higher by quality score.
| XENE | YDES | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $33.49 | $5.92 |
| 12-month range | $33.49–$70.96 | $1.90–$17.61 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #276 of 301 Healthcare | #277 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: XENE fair value analysis · YDES fair value analysis